Current molecular pharmacology最新文献

筛选
英文 中文
EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma. EGFR抑制剂CL-387785抑制肺腺癌的进展。
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467215666220329212300
Yong Cai, Zhaoying Sheng, Zhiyi Dong, Jiying Wang
{"title":"EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma.","authors":"Yong Cai,&nbsp;Zhaoying Sheng,&nbsp;Zhiyi Dong,&nbsp;Jiying Wang","doi":"10.2174/1874467215666220329212300","DOIUrl":"https://doi.org/10.2174/1874467215666220329212300","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the influence of the irreversible EGFR inhibitor CL-387785 on invasion, metastasis, and radiation sensitization of non-small cell lung cancer cells.</p><p><strong>Methods: </strong>The proliferation inhibitory rate at different time points was detected by MTT assay. The apoptosis of H1975 cells treated with CL-387785 was detected using flow cytometry. The invasion and migration of H1975 cells treated with CL-387785 were determined by Transwell assay and wound healing assay. The survival fraction (SF) of H1975 cells cultured with CL- 387785 under X-ray (0, 2, 4, 6, 8, and 10 Gy) was detected by cloning formation experiment, and the sensitization ratio (SER) was calculated by clicking the multi-target model to fit the cell survival curve.</p><p><strong>Results: </strong>CL-387785 restrained H1975 cell proliferation in a concentration- and time-dependent manner. CL-387785 promoted H1975 cell apoptosis and reduced cell migration distance and the number of transmembrane cells. The SF treated by different concentrations of CL-387785 (10, 25, 50, and 100 nM) was all below 0 nM. The radiation SER of CL-387785 (10, 25, 50 and 100 nM) were 1.17, 1.39, 2.88, and 3.64, respectively.</p><p><strong>Conclusion: </strong>The invasion and metastasis of H1975 cells were restrained by irreversible EGFR inhibitor CL-387785. CL-387785 also exhibited the effect of radiotherapy sensitization.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9254245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effect of Curcumin on the Head and Neck Squamous Cell Carcinoma Cell Line HN5. 姜黄素对头颈部鳞状细胞癌HN5细胞的影响。
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467215666220414143441
Elaheh Dalir Abdolahinia, Shahin Ahmadian, Sepideh Bohlouli, Faezeh Jafarmadar Gharehbagh, Negar Ghorbani Jahandizi, Sepideh Zununi Vahed, Yalda Rahbar Saadat, Amirala Aghbali, Simin Sharifi, Solmaz Maleki Dizaj, Khalaf F Alsharif, Haroon Khan
{"title":"Effect of Curcumin on the Head and Neck Squamous Cell Carcinoma Cell Line HN5.","authors":"Elaheh Dalir Abdolahinia,&nbsp;Shahin Ahmadian,&nbsp;Sepideh Bohlouli,&nbsp;Faezeh Jafarmadar Gharehbagh,&nbsp;Negar Ghorbani Jahandizi,&nbsp;Sepideh Zununi Vahed,&nbsp;Yalda Rahbar Saadat,&nbsp;Amirala Aghbali,&nbsp;Simin Sharifi,&nbsp;Solmaz Maleki Dizaj,&nbsp;Khalaf F Alsharif,&nbsp;Haroon Khan","doi":"10.2174/1874467215666220414143441","DOIUrl":"https://doi.org/10.2174/1874467215666220414143441","url":null,"abstract":"<p><strong>Background: </strong>Curcumin has been isolated from the rhizomes of Curcuma longa. Over the years, it has shown outstanding therapeutic potential in various human disorders, including cancers.</p><p><strong>Objective: </strong>The aim is to study curcumin's effects on the apoptosis signaling pathway in the head and neck squamous cell carcinoma (HNSCC) cell line HN5.</p><p><strong>Methods: </strong>The cytotoxicity of curcumin on HN5 cells were assessed. In addition, HN5 cells were also treated with curcumin to evaluate its effect on the caspase-8, -9, Bcl-2, Bax, and Stat3 gene expressions.</p><p><strong>Results: </strong>The results exhibited that cell viability reduced following curcumin treatment in a concentration- dependent manner. Curcumin treatment caused decreased expression of Bcl2, with simultaneous upregulation of the Bax/Bcl2 ratio. Curcumin increased caspase-9 expression, did not affect caspase-8, and decreased Stat3 expression. The induction of the mitochondria-dependent apoptosis pathway of curcumin happened by modulating the expression of Bcl2 and Bax genes, resulting in the caspase-9 activation. Furthermore, curcumin decreased the expression of the Stat3 in HN-5 cells.</p><p><strong>Conclusions: </strong>In conclusion, curcumin showed marked anticancer effects in the HN-5 cell line by modulating Stat-3; Bax/Bcl-2 expression in vitro.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9493600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Role of SIRT-1 as a Target for Treatment and Prevention of Diabetic Nephropathy: A Review. SIRT-1作为治疗和预防糖尿病肾病的靶点的作用:综述
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467216666230109140134
Anita Kumari, Nalini Sodum, V Ravichandiran, Nitesh Kumar
{"title":"Role of SIRT-1 as a Target for Treatment and Prevention of Diabetic Nephropathy: A Review.","authors":"Anita Kumari,&nbsp;Nalini Sodum,&nbsp;V Ravichandiran,&nbsp;Nitesh Kumar","doi":"10.2174/1874467216666230109140134","DOIUrl":"https://doi.org/10.2174/1874467216666230109140134","url":null,"abstract":"<p><p>Type-2 diabetes mellitus is a prime factor for the development of Diabetic Nephropathy (DN) that affects the vital organ namely the kidneys, and further alters the functions of the nephron system. DN is nowadays becoming a challenge for scientists towards the world because of its high pervasiveness and complexity of medication. Various risk factors are involved in the initiation of pathogenic DN, which are associated with different pathways against drug activity. Due to this DN becomes an unpredictable query to the researchers. SIRT1 is a silent information regulator factor 2 related enzyme 1 (SIRT1) is nicotinamide adenine dinucleotide (NAD+) dependent deacetylase that functions as an intracellular regulator of transcriptional activity. An activated version of SIRT-1 improves the metabolic diseased conditions associated with other molecular pathways. SIRT1 attenuates diabetic nephropathy in in vitro and in vivo experimental models of diabetes containing Podocytes, Mesangial cells, and Renal proximal tubular cells. SIRT1 shows nephroprotective effects in DN in part through deacetylation of transcription factors i.e., imply in the disease like p53, PTP1B, FOXO, RelA, NF- kβ, STAT-3, and PGC-1α/ PPARγ. It has been shown that some natural products like resveratrol and synthetic compounds are activating the SIRT1, this further involved the cascade pathways to prevent the DN. This review will help regarding the effectiveness of SIRT1as target in the prevention and treatment of DN.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9563869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Berberine: Is it a Promising Agent for Mental Disorders Treatment? 小檗碱:它是一种有前途的精神障碍治疗药物吗?
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467215666220509213122
Mehran Shayganfard
{"title":"Berberine: Is it a Promising Agent for Mental Disorders Treatment?","authors":"Mehran Shayganfard","doi":"10.2174/1874467215666220509213122","DOIUrl":"https://doi.org/10.2174/1874467215666220509213122","url":null,"abstract":"<p><p>Effective and better-tolerated agents for the treatment of most of psychiatric disorders are one of the main challenges. Recently, anti-inflammatory, antioxidants and neuroprotective agents as adjuvant therapy have been shown to be able to play a role against the degenerative mechanisms commonly related to psychiatric conditions. Berberine, a biologically active alkaloid derived from various plants, represents many pharmacological impacts, such as antimicrobial, antidiabetic, anticancer, antioxidant and anti-inflammatory activities. This compound also protects neurons and improves the survival, growth and action of nerve cells due to its high potential for crossing the blood-brain barrier. Ample evidence reported that berberine had been associated with CNS-related disorders, including Alzheimer's, cerebral ischemia, mental depression, schizophrenia and anxiety. Thus, in this review, we aimed to indicate the effectiveness of berberine on mental disorders.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Research Progress and Future Development Potential of Oridonin in Pharmacological Activities. 冬凌草苷药理活性的研究进展及未来开发潜力。
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467216666221130163634
Shiying Ye, Shaowei Sun, Jiye Cai, Jinhuan Jiang
{"title":"Research Progress and Future Development Potential of Oridonin in Pharmacological Activities.","authors":"Shiying Ye,&nbsp;Shaowei Sun,&nbsp;Jiye Cai,&nbsp;Jinhuan Jiang","doi":"10.2174/1874467216666221130163634","DOIUrl":"https://doi.org/10.2174/1874467216666221130163634","url":null,"abstract":"<p><p>In recent years, attention has increasingly focused on herbal medicines and their bioactive components attributed to their multi-target pharmacological activity and low side effects. Oridonin is a natural diterpenoid extracted from the traditional Chinese herb and is one of the main active components of Rabdosia rubescens. Modern pharmacological studies have shown that oridonin has anti-tumor, anti-bacterial, anti-inflammatory, anti-oxidant, cardiovascular protective, immunomodulatory, and other effects. Based on the published literature in recent years, we outline the pharmacological activities of oridonin, aiming to provide a theoretical basis for the design and development of new oridonin-based drugs, as well as to facilitate the process of oridonin for clinical use.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9842705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoplasmic Reticulum Stress and Renin-Angiotensin System Crosstalk in Endothelial Dysfunction. 内皮功能障碍中的内质网应激和肾素-血管紧张素系统串扰。
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467215666220301113833
Himanshu Sankrityayan, Pooja Dhileepkumar Rao, Vishwadeep Shelke, Yogesh A Kulkarni, Shrikant R Mulay, Anil Bhanudas Gaikwad
{"title":"Endoplasmic Reticulum Stress and Renin-Angiotensin System Crosstalk in Endothelial Dysfunction.","authors":"Himanshu Sankrityayan,&nbsp;Pooja Dhileepkumar Rao,&nbsp;Vishwadeep Shelke,&nbsp;Yogesh A Kulkarni,&nbsp;Shrikant R Mulay,&nbsp;Anil Bhanudas Gaikwad","doi":"10.2174/1874467215666220301113833","DOIUrl":"https://doi.org/10.2174/1874467215666220301113833","url":null,"abstract":"<p><strong>Background: </strong>Vascular endothelial dysfunction (VED) significantly results in catastrophic cardiovascular diseases with multiple aetiologies. Variations in vasoactive peptides, including angiotensin II and endothelin 1, and metabolic perturbations like hyperglycaemia, altered insulin signalling, and homocysteine levels result in pathogenic signalling cascades, which ultimately lead to VED. Endoplasmic reticulum (ER) stress reduces nitric oxide availability, causes aberrant angiogenesis, and enhances oxidative stress pathways, consequently promoting endothelial dysfunction. Moreover, the renin-angiotensin system (RAS) has widely been acknowledged to impact angiogenesis, endothelial repair and inflammation. Interestingly, experimental studies at the preclinical level indicate a possible pathological link between the two pathways in the development of VED. Furthermore, pharmacological modulation of ER stress ameliorates angiotensin-II mediated VED as well as RAS intervention either through inhibition of the pressor arm or enhancement of the depressor arm of RAS, mitigating ER stress-induced endothelial dysfunction and thus emphasizing a vital crosstalk.</p><p><strong>Conclusion: </strong>Deciphering the pathway overlap between RAS and ER stress may open potential therapeutic avenues to combat endothelial dysfunction and associated diseases. Several studies suggest that alteration in a component of RAS may induce ER stress or induction of ER stress may modulate the RAS components. In this review, we intend to elaborate on the crosstalk of ER stress and RAS in the pathophysiology of VED.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9259423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of the Relationship between Aromatase/Sirtuin1 Interaction and miRNA Expression in Human Neuroblastoma Cells. 人神经母细胞瘤细胞中芳香化酶/Sirtuin1相互作用与miRNA表达关系的研究
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467215666220510112118
Yasemin Kartal, Unal Metin Tokat, Pelin Kelicen-Ugur, Serkan Yılmaz, Sevilay Karahan, Murat Timur Budak
{"title":"Evaluation of the Relationship between Aromatase/Sirtuin1 Interaction and miRNA Expression in Human Neuroblastoma Cells.","authors":"Yasemin Kartal,&nbsp;Unal Metin Tokat,&nbsp;Pelin Kelicen-Ugur,&nbsp;Serkan Yılmaz,&nbsp;Sevilay Karahan,&nbsp;Murat Timur Budak","doi":"10.2174/1874467215666220510112118","DOIUrl":"https://doi.org/10.2174/1874467215666220510112118","url":null,"abstract":"<p><strong>Background: </strong>Changes in activation/inhibition of Sirtuin-1 (SIRT1) and aromatase play an important role in a plethora of diseases. MicroRNAs (miRNAs) modulate multiple molecular pathways and affect a substantial number of physiological and pathological processes.</p><p><strong>Objective: </strong>The aim of this study was to investigate any possible interaction between aromatase and SIRT1 in SH-SY5Y cells and to see how there is a connection between this interaction and miRNA expression, if there is an interaction.</p><p><strong>Methods: </strong>In this study, cells were incubated in serum-deprived media for 6, 12, and 24 h. Aromatase and SIRT1 expressions were evaluated by Western blot. The IC50 concentration of SIRT1 activator (SRT1720), SIRT1 inhibitor (EX527), and aromatase inhibitors (letrozole and fadrozole) was determined by the XTT method. Then, CYP19A1 and SIRT1 levels were evaluated in the presence of SIRT1 siRNA or IC50 values for each activator/inhibitor. Finally, CYP19A1, SIRT1 expression and miRNA target gene were assessed with bioinformatic approaches.</p><p><strong>Results: </strong>Aromatase and SIRT1 protein levels were significantly elevated in the cells incubated at 24 h in serum-deprived media (p ≤ 0.05). SIRT1 also positively regulated CYP19A1 in SH-SY5Y cells in media with/without FBS. Serum deprivation depending on time course caused changes in the oxidant/ antioxidant system. While oxidative stress index tended to decrease in the absence of FBS at 24 h compared to the control, it showed a significant decrease at 48 h in a serum-deprived manner (p ≤ 0.001). As a result of bioinformatics analysis, we determined 3 miRNAs that could potentially regulate SIRT1 and CYP19A1. hsa-miR-27a-3p and hsa-miR-181a-5p correlated in terms of their expressions at 24 h compared to 12 h, and there was a significant decrease in the expression of these miRNAs. On the contrary, the expression of hsa-miR-30c-5p significantly increased at 24 h compared to 12 h.</p><p><strong>Conclusion: </strong>Considering the results, a direct link between aromatase and SIRT1 was observed in human neuroblastoma cells. The identification of key miRNAs, hsa-miR-27a-3p, hsa-miR-30c-5p, and hsa-miR-181a-5p targeting both aromatase and SIRT1, provides an approach with novel insights on neurology-associated diseases.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9487116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethoxidol as a Broad-spectrum Adaptogen. 乙氧基醇作为广谱适应原。
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467215666220308115514
Zhigacheva Irina V, Krikunova Natalya I, Binyukov Vladimir, Mil Elena M, Rusina Irina F, Goloshchapov Alexander
{"title":"Ethoxidol as a Broad-spectrum Adaptogen.","authors":"Zhigacheva Irina V,&nbsp;Krikunova Natalya I,&nbsp;Binyukov Vladimir,&nbsp;Mil Elena M,&nbsp;Rusina Irina F,&nbsp;Goloshchapov Alexander","doi":"10.2174/1874467215666220308115514","DOIUrl":"https://doi.org/10.2174/1874467215666220308115514","url":null,"abstract":"<p><strong>Background: </strong>Stress factors lead to a shift in the antioxidant-prooxidant relationship, allowing an increase in the generation of reactive oxygen species (ROS) by mitochondria, which results in the development of oxidative stress. Consequently, it is possible to put forward an assumption that drugs which reduce the excessive generation of ROS by these organelles should increase the body's resistance to stress factors. Antioxidants can be used as such drugs. In this regard, the aim of this work was to study the bioenergetics characteristic of mitochondria under stress conditions and under the action of 2-ethyl-6-methyl-3-hydroxypyridinium hydroxybutanedioate (ethoxidol).</p><p><strong>Methods: </strong>The antiradical activity of the drug was evaluated by the chemiluminescent method (CL). The functional state of the mitochondria was studied with reference to the level of lipid peroxidation by the spectrofluorimetry and in terms of fatty acid composition of mitochondrial membranes using the chromatography technique. The study of mitochondrial morphology was performed employing the method of atomic force microscopy.</p><p><strong>Results: </strong>The injection in mice of ethoxidol at a dose of 10<sup>-5</sup> mol/kg for 7 days led to the prevention of the stress-induced increase in the intensity of LPO in the membranes of the mitochondria, and swelling of these organelles; it also prevented a decrease in the content of unsaturated fatty acids, containing 18 and 20 carbon atoms. At the same time, ethoxidol increased the life expectancy of mice by 3.0-4.2 times in conditions of various types of hypoxia.</p><p><strong>Conclusion: </strong>The adaptogenic properties of ethoxidol can be attributed to its antiradical and antioxidant properties.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9493595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MiR-129-2-3p Inhibits Esophageal Carcinoma Cell Proliferation, Migration, and Invasion via Targeting DNMT3B. MiR-129-2-3p通过靶向DNMT3B抑制食管癌细胞增殖、迁移和侵袭
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467215666220308122716
Xuyang Peng, Xuhui Wu, Gongzhi Wu, Chongxiong Peng, Bin Huang, Mingjiang Huang, Jianyang Ding, Chaofan Mao, Huaizhong Zhang
{"title":"MiR-129-2-3p Inhibits Esophageal Carcinoma Cell Proliferation, Migration, and Invasion <i>via</i> Targeting DNMT3B.","authors":"Xuyang Peng,&nbsp;Xuhui Wu,&nbsp;Gongzhi Wu,&nbsp;Chongxiong Peng,&nbsp;Bin Huang,&nbsp;Mingjiang Huang,&nbsp;Jianyang Ding,&nbsp;Chaofan Mao,&nbsp;Huaizhong Zhang","doi":"10.2174/1874467215666220308122716","DOIUrl":"https://doi.org/10.2174/1874467215666220308122716","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to explore the regulatory mechanism of miR-129-2-3p underlying esophageal carcinoma (EC) cell progression and generate new ideas for targeted treatment of EC.</p><p><strong>Methods: </strong>Mature miRNA expression data and total RNA sequencing data of EC in the TCGAESCA dataset were utilized to explore differentially expressed miRNAs (DEmiRNAs). StarBase database was then utilized to predict targets of miRNA. MiR-129-2-3p and DNMT3B expression in EC cell lines was assayed through qRT-PCR and Western blot. CCK-8, scratch healing, and transwell assays were conducted to assess the impact of miR-129-2-3p on EC cell phenotypes. In addition, a dual-luciferase assay was completed to identify the binding relationship between DNMT3B and miR-129-2-3p.</p><p><strong>Results: </strong>MiR-129-2-3p was noticeably less expressed in EC cell lines, while DNMT3B was highly expressed. MiR-129-2-3p could bind to DNMT3B. Furthermore, in vitro functional experiments uncovered that overexpressed miR-129-2-3p repressed EC cell progression while further overexpressing DNMT3B would restore the above inhibitory effect.</p><p><strong>Conclusion: </strong>MiR-129-2-3p is a cancer repressor in EC cells, and it could target DNMT3B, thus hampering the progression of EC cells.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9493596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives. 心血管疾病的PCSK9生物标志物和关键调节剂:预示着一个新的治疗时代及其未来展望。
IF 2.7 4区 生物学
Current molecular pharmacology Pub Date : 2023-01-01 DOI: 10.2174/1874467216666221202144813
Jitendra Gupta, Reena Gupta
{"title":"PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives.","authors":"Jitendra Gupta,&nbsp;Reena Gupta","doi":"10.2174/1874467216666221202144813","DOIUrl":"https://doi.org/10.2174/1874467216666221202144813","url":null,"abstract":"<p><p>Cardiovascular disorders (CVDs) are the leading cause of death worldwide and are accelerated via the low level of low-density lipoprotein-cholesterol (LDL-C). The proprotein convertase subtilis/kexin type9 (PCSK9), a vital regulator and a biomarker, circulates for the LDL-C and has the degradation capability of the low-density lipoprotein receptor (LDLR). PCSK9 has modulated the overall mechanism by transcription, secretion, clearance, or extracellular inactivation in the past few years.PCSK9 has specific pathophysiological roles in many cardiovascular cells. The initial data on the PCSK9 inhibitor, Evolocumab, has a specific reduction in the composite end-point, such as cardiovascular, myocardial, and stroke, while the rest of the data release is still under wait. Furthermore, it is witnessed that the U.S. and the European authorities have approved two humanized antibodies against the LDL-R binding site of PCSK9. This review highlighted the recent data findings on the PCSK9 and its regulation, focusing on cardiovascular disorders, and summarized the current clinical studies. Thus it provides a ray of hope to overcome statin intolerance and alternative approaches for PSCK9 inhibition and significantly reduce cardiovascular complications. This review plays a pivotal role for the researchers and scientists working on PCSK9 inhibitors to treat cardiovascular disorders.</p>","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9557151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信